Furthermore, the ongoing LAURA phase III trial (NCT03521154) which is evaluating the role of osimertinib as maintenance therapy in patients with unresectable stage III NSCLC with EGFRm following cCRT will provide important evidence if EGFR-targeted therapy is beneficial for survival gain in unresectable stage III NSCLC with EGFR-mutated patients (40). This evidence concerns the gene EGFR and non-small cell lung carcinoma.